Personalized mRNA Vaccine Cuts Melanoma Death or Recurrence Risk by 42%
🤖 AI-generated content — The title and summary were produced automatically by artificial intelligence, without human editorial review.
Merck and Moderna said their personalized mRNA vaccine reduced the risk of melanoma recurrence or death by 42% compared with standard treatment in a late-stage trial. The companies are discussing approval with regulators, with full results due at a Madrid oncology conference.
Continue in the app — vote & join in ➔Source: Ars Technica · via ahirlevel.hu